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The association between HLA homozygosity and measles-specific Th1 (IFN-γ, IL-2 and IL-12p40) and Th2 (IL-4 and IL-10) cytokine
responses were assessed in a group of 339 healthy schoolchildren 12–18 years of age previously immunized with two doses of live-attenuated
measles virus vaccine. No associations were observed between class I HLA homozygosity and measles-specific cytokine levels. Children who
were homozygous at the class II DRB1, DQA1, DPA1 and DPB1 loci had higher median IFN-γ secretion levels compared with children who were
heterozygous for DRB1 (77.7 vs. 39.5 pg/ml, p=0.05), DQA1 (60.9 vs. 36.6 pg/ml, p=0.03), DPA1 (46.1 vs. 27.1 pg/ml, p=0.01) and DPB1
(61.5 vs. 36.0 pg/ml, p=0.01) loci, respectively. Homozygosity at increasing numbers of HLA loci ( >=4) was associated with increased IFN-γ
secretion levels (test for trend p-value=0.01). Our results suggest that HLA homozygosity showed no disadvantage for measles-specific cytokine
responses and instead was associated with increased IFN-γ levels.
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Immune responses to measles virus (MV) immunization
result from the interaction of the virus and a variety of immune
response genes, particularly host human leukocyte antigen
(HLA) genes. Given its important role in antigen presentation,
polymorphisms in the HLA genes restrict T lymphocyte res-
ponses to measles thereby influencing measles vaccine virus-
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doi:10.1016/j.virol.2007.02.028The genetic basis for the variation in the immune response to
viruses, including hepatitis B, influenza, and HIV-1, has been
recognized (Kruskall et al., 1992; Gelder et al., 2002; Kaslow et
al., 2001; Newport et al., 2004). Specific class I and class II
HLA alleles have been associated with the spectrum of immune
response to measles vaccine (Poland et al., 2001; St.Sauver et
al., 2002; Jacobson et al., 2003; Ovsyannikova et al., 2004b). In
particular, children who were homozygous for alleles within
classes IB and DQA1 were found more likely to be seronegative
than children who were heterozygous at these loci (St.Sauver
et al., 2002).
Theoretically, HLA homozygosity – defined as “inheritance
of two identical alleles at each polymorphic locus” – may limit
the repertoire of immune responses by reducing the diversity
of pathogen-derived peptides which can be displayed on the
surface of antigen-presenting cells (“the heterozygote advan-
tage”) and confers an unfavorable prognosis following
infection (Thursz et al., 1997; Tang et al., 1999; Trachtenberg
Table 1
Comparison of locus-specific homozygosity rates across gender
HLA locus Number of homozygous
males (%)
Number of homozygous
females (%)
P-value a
HLA-A 42 (23.3) 31 (19.5) 0.39
HLA-B 17 (9.4) 10 (6.3) 0.28
HLA-Cw 35 (19.4) 20 (12.6) 0.09
HLA-DRB1 26 (14.4) 18 (11.3) 0.39
HLA-DQA1 49 (28.2) 38 (24.5) 0.45
HLA-DQB1 63 (35.0) 55 (34.6) 0.93
HLA-DPA1 111 (63.8) 115 (74.7) 0.03
HLA-DPB1 47 (26.1) 53 (33.3) 0.14
a P-value compares distributions of homozygosity across gender using χ2
tests of significance. Results significant at a p-value≤0.05 are highlighted in
bold.
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previous studies demonstrated an association between
homozygosity, or reduced HLA diversity, and decreased
measles-induced antibody levels following a single dose of
vaccine (St.Sauver et al., 2002). However, two doses of
measles vaccine could overcome this barrier and induced
protective antibody levels and lymphoproliferative immune
responses regardless of HLA homozygosity status (St.Sauver
et al., 2005). Associations between HLA homozygosity and
cytokine immune responses to viral vaccines, such as
measles, in a genetically diverse population have not been
well studied. To address the fundamental question of whether
the mechanism of lower vaccine-induced antibody levels in
the context of HLA homozygosity were related to low
vaccine-induced cytokine levels, we examined the relation-
ship between class I and class II HLA homozygosity and
Th1 (interferon gamma [IFN-γ], interleukin-2 [IL-2], and
IL-12p40)/Th2 (IL-4 and IL-10) cytokine immune responses.
The study presented here provided an opportunity to assess
for the first time the relative contribution of homozygous
HLA genotypes in the control of cytokine immune responses
in adolescents.
Results
Study population and measles-specific cytokine responses
In total, 339 children were enrolled in the study ranging in
age from 12 to 18 years. The majority of the children were
white (93%) and the median age of participants at the first
and second immunization was 15.6 months and 12.1 years,
respectively. The median time from second immunization to
blood draw was 4.7 years. There were a total of 159 (47%)
girls and 180 (53%) boys in the study. IFN-γ, IL-4, and IL-10
cytokine responses to MV within the total population were
similar between genders (median IFN-γ secretion of 49.7 pg/
ml for girls versus 31.4 pg/ml for boys [p=0.39], median
IL-4 secretion of 9.3 pg/ml for girls versus 10.0 pg/ml for
boys [p=0.72], and median IL-10 secretion of 32.0 pg/ml for
girls versus 24.5 pg/ml for boys [p=0.19], respectively). IL-2
cytokine responses were below the minimum detection limit
(median IL-2 secretion of -1.9 pg/ml for girls versus −2.8 pg/
ml for boys [p=0.51]). Examination of measles-specific
IL-12p40 cytokine responses revealed that girls had margin-
ally higher IL-12p40 cytokine responses than boys (median
9.0 pg/ml for girls versus 6.5 pg/ml for boys, respectively
[p=0.07]). Rates of class I A, B, Cw, and class II DRB1,
DQA1, DQB1, or DPB1 homozygosity did not differ
significantly by gender. However, DPA1 homozygosity was
significantly different between genders: 111 (64%) of the
boys and 115 (75%) of the girls were homozygous at the
DPA1 locus (p=0.03) (Table 1). We also found that specific
A⁎02, B⁎44, Cw⁎07, DRB1⁎15/16, DQA1⁎01, DQB1⁎03,
DPA1⁎01, and DPB1⁎04 alleles accounted for 48%, 22%,
56%, 25%, 62%, 37%, 91%, and 88% of the A, B, Cw,
DRB1, DQA1, DQB1, DPA1 and DPB1 alleles, respectively.
No violations of Hardy–Weinberg equilibrium were found forHLA-A (p=0.38), B (p=0.91), DRB1 (p=0.11), DQA1
(p=0.09), DPA1 (p=0.12), or DPB1 (p=0.61) loci. However,
a comparison of allele distributions for the HLA-Cw and
HLA-DQB1 loci revealed possible departures from equili-
brium (p=0.03 and p<0.001, respectively). As a result, sta-
tistical comparisons involving the Cw and DQB1 loci should
be viewed with caution.
HLA homozygosity and cytokine immune responses
No associations were observed between HLA class I A, B or
Cw homozygosity and measles-specific Th1-like (IFN-γ, IL-2,
and IL-12p40) cytokine levels (p=0.11 to 0.95) (Table 2).
However, significant associations with class II loci were
observed for IFN-γ responses following measles vaccination.
Children who were homozygous at class II DRB1, DQA1,
DPA1 and DPB1 loci had significantly higher median IFN-γ
secretion levels compared with children who were heterozygous
for DRB1 (77.7 vs. 39.5 pg/ml, p=0.05), DQA1 (60.9 vs.
36.6 pg/ml, p=0.03), DPA1 (46.1 vs. 27.1 pg/ml, p=0.01) and
DPB1 (61.5 vs. 36.0 pg/ml, p=0.01) loci, respectively (Table
2). Measles-specific IL-2 cytokine immune responses were
below minimum detectable value. Measles-induced IL-12p40
cytokine immune responses were low and demonstrated no
evidence of genetic regulation by any of the loci considered
(p=0.14 to 0.88). Since the DPA1 locus was not very
polymorphic in our population (DPA1⁎0103 and DPA1⁎0201
accounted for 77% and 17% of the DPA1 alleles, respectively)
and 226 (70%) of the children in the study were homozygous at
this locus, we excluded DPA1 in the overall homozygosity
analyses.
The relationship between HLA homozygosity and measles-
induced Th2-like (IL-4 and IL-10) cytokine immune responses
was also examined. The median IL-4 secretion levels among
children who were homozygous at the class IA locus was
marginally significantly different from the median IL-4 levels
among children who were heterozygous at this locus (9.1 vs.
10.3 pg/ml, p=0.07) (Table 3). Children who were homozygous
at the DQA1 locus had suggestive evidence of higher median
measles-specific IL-10 levels compared with children who were
heterozygous for DQA1 (32.7 vs. 26.0 pg/ml, p=0.06).
However, multilocus homozygosity was not associated with
Table 2
Differences in distribution of measles-specific IFN-γ, IL-2 and IL-12p40 responses between children heterozygous and homozygous for specific HLA loci
HLA
locus
IFN-γ secretion (pg/ml) IL-2 secretion (pg/ml) IL-12p40 secretion (pg/ml)
Homozygotes,
N
Heterozygotes,
median (IQR)
Homozygotes,
median (IQR)
p-value a Homozygotes,
N
Heterozygotes,
median (IQR)
Homozygotes,
median (IQR)
p-value a Homozygotes,
N
Heterozygotes,
median (IQR)
Homozygotes,
median (IQR)
p-value a
A 73 40.76
(6.88, 195.79)
40.59
(13.46, 109.92)
0.81 73 −2.84
(−15.59, 14.70)
0.65
(−10.50, 11.39)
0.65 73 8.81
(3.0, 18.0)
6.0
(2.0, 14.0)
0.14
B 27 43.51
(9.66, 189.07)
9.78
(−1.37, 97.17)
0.11 27 −2.27
(−15.25, 13.56)
−2.44
(−10.15, 15.89)
0.74 27 8.0
(2.04, 18.0)
5.0
(1.96, 9.0)
0.19
Cw 55 40.84
(8.94, 189.07)
38.79
(1.17, 115.65)
0.95 55 −3.21
(−14.88, 13.17)
3.07
(−15.59, 15.89)
0.58 55 8.0
(2.0, 16.0)
8.0
(3.0, 19.0)
0.58
DRB1 44 39.57
(7.92, 167.11)
77.77
(11.68, 329.28)
0.05 43 −1.94
(−15.25, 13.19)
−4.22
(−14.53, 15.89)
0.97 44 8.0
(2.0, 17.5)
7.0
(1.5, 15.0)
0.88
DQA1 87 36.69
(6.88, 154.13)
60.98
(13.46, 226.8)
0.03 86 −2.86
(−15.42, 13.7)
0.32
(−14.72, 14.7)
0.62 87 7.0
(2.0, 17.0)
9.0
(1.0, 18.0)
0.50
DQB1 118 38.79
(9.0, 148.81)
48.74
(7.92, 264.28)
0.27 116 −2.77
(−15.42, 13.7)
−1.78
(−14.52, 14.62)
0.53 118 8.0
(2.0, 16.5)
8.08
(2.04, 18.00)
0.55
DPA1 226 27.19
(3.72, 97.46)
46.18
(9.79, 205.73)
0.01 224 −0.8
(−12.78, 17.74)
−2.83
(−15.43, 13.39)
0.11 225 7.5
(3.0, 13.0)
8.0
(2.0, 18.0)
0.70
DPB1 100 36.03
(5.67, 133.48)
61.52
(13.52, 247.59)
0.01 100 −1.76
(−14.85, 14.54)
−3.63
(−15.13, 13.18)
0.30 100 7.0
(2.0, 15.67)
9.92
(3.5, 19.0)
0.15
Any
locus b
259 34.91
(2.74, 120.84)
46.29
(9.64, 211.75)
0.13 257 −4.03
(−17.16, 12.21)
−1.81
(−14.53, 13.89)
0.48 259 7.0
(2.0, 13.0)
8.0
(2.0, 18.0)
0.52
a Linear regression analysis. P-values were calculated using rank-transformed values; p-values adjusted for age at enrollment, age at first MMR vaccination, age at second MMR vaccination, gender, and race. Results
significant at a p-value≤0.05 are highlighted in bold.
b Analysis does not include DPA1.
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Table 3
Differences in distribution of measles-specific IL-4 and IL-10 responses between children heterozygous and homozygous for specific HLA loci
HLA locus IL-4 secretion (pg/ml) IL-10 secretion (pg/ml)
Homozygote,
N
Heterozygote,
median (IQR)
Homozygote,
median (IQR)
p-value a Homozygote,
N
Heterozygote,
median (IQR)
Homozygote,
median (IQR)
p-value a
A 73 10.38 (4.29, 24.82) 9.1 (0.0, 21.75) 0.07 73 28.5 (10.0, 72.5) 29.5 (11.0, 74.5) 0.78
B 27 9.65 (2.53, 24.37) 10.86 (2.8, 22.51) 0.99 27 29.5 (10.0, 75.5) 24.0 (14.5, 41.5) 0.47
Cw 55 9.65 (2.12, 24.63) 10.86 (4.91, 23.11) 0.65 55 29.5 (11.5, 74.5) 25.0 (−4.0, 52.0) 0.24
DRB1 44 9.85 (2.3, 24.82) 9.22 (4.35, 21.17) 0.69 43 28.5 (8.5, 74.5) 32.5 (13.0, 70.0) 0.30
DQA1 87 9.59 (2.05, 23.85) 9.55 (4.29, 23.88) 0.55 86 26.0 (7.75, 69.75) 32.75 (14.0, 84.5) 0.06
DQB1 118 10.29 (2.95, 24.2) 8.54 (2.22, 24.82) 0.57 116 26.0 (8.5, 78.25) 32.75 (12.5, 66.0) 0.87
DPA1 226 9.14 (1.02, 19.58) 9.92 (4.19, 25.34) 0.77 224 22.5 (10.0, 47.0) 32.75 (10.75, 78.0) 0.17
DPB1 100 10.07 (3.99, 25.65) 8.73 (0.92, 20.69) 0.16 100 29.0 (10.25, 75.5) 28.0 (8.0, 69.5) 0.49
Any locus b 259 10.02 (4.06, 25.57) 9.59 (2.19, 23.11) 0.75 257 25.5 (9.5, 81.5) 32.0 (10.5, 71.0) 0.93
a Linear regression analysis. P-values were calculated using rank-transformed values; p-values adjusted for age at enrollment, age at first MMR vaccination, age at
second MMR vaccination, gender, and race.
b Analysis does not include DPA1.
Table 4
Differences in distribution of measles-specific cytokine responses among
children homozygous for increasing numbers of HLA loci
Number of
homozygous loci
N Median cytokine secretion
values (IQR), pg/ml
P-value a
IFN-γ secretion
0 42 22.32 (0.49, 88.29) 0.01
1 76 42.53 (9.39, 161.45)
2 100 40.46 (7.10, 123.30)
3 61 57.74 (15.31, 277.78)
≥4 60 56.67 (3.90, 229.90)
IL-2 secretion
0 42 −1.36 (−12.12, 12.21) 1.00
1 75 −4.16 (−16.19, 17.74)
2 99 −2.84 (−14.88, 13.80)
3 60 −3.88 (−15.16, 8.40)
≥4 60 3.66 (−12.78, 18.31)
IL-12p40 secretion
0 42 7.00 (3.00, 11.00) 0.76
1 75 9.00 (2.00, 18.00)
2 100 7.00 (2.00, 17.00)
3 61 9.83 (3.00, 18.00)
≥4 60 7.08 (3.00, 17.00)
IL-4 secretion
0 42 7.37 (1.22, 19.58) 0.54
1 76 11.56 (4.84, 27.34)
2 100 11.12 (2.26, 25.65)
3 61 10.48 (4.52, 25.34)
≥4 60 7.43 (1.50, 20.22)
IL-10 secretion
0 42 20.25 (10.00, 37.00) 0.62
1 75 30.50 (6.50, 86.50)
2 99 36.00 (6.00, 78.50)
3 60 32.25 (14.00, 72.00)
≥4 60 27.00 (10.25, 55.25)
a Linear regression analysis test for trend; calculated using rank-transformed
values; p-values adjusted for age at enrollment, age at first MMR vaccination,
age at second MMR vaccination, gender, and race. Results significant at a
p-value≤0.05 are highlighted in bold.
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0.93, respectively).
Finally, we examined the associations between homozygosity
at increasing number of HLA loci (including DPA1) and
measles-induced cytokine secretion levels. Homozygosity at
increasing numbers of HLA loci (≥4) was associated with
increased IFN-γ secretion levels (test for trend p-value=0.01)
(Table 4). Homozygosity at increasing numbers of HLA loci was
not, however, associated with differences in IL-2, IL-12p40,
IL-4 or IL-10 secretion levels. All analyses described above
defined homozygosity based on the two-digit molecular
designation. We re-assessed associations using the four-digit
designation and found similar associations with homozygosity,
albeit with fewer individuals classified as homozygous.
Discussion
We found little evidence that either homozygosity at specific
HLA loci or overall homozygosity had any disadvantage in
terms of measles vaccine-induced cytokine immune responses
after two doses of measles vaccine. If anything, our study
suggests that class II HLA homozygosity is associated with
increased IFN-γ levels following two doses of measles vaccine.
Moreover, we found that homozygosity at increasing numbers
of HLA loci was associated with increased IFN-γ secretion
levels, signifying the role of HLA molecules in the control of
immune responses to MV. This may indicate that IFN-γ is
important for immunity to measles; however, it is unknown how
homozygosity and polymorphic differences within HLA loci
affect peptide binding, T lymphocyte recognition, and hence the
outcome of IFN-γ production. It is clear that more work needs
to be done to elucidate the exact mechanism for increased
IFN-γ levels in HLA homozygous individuals. Our results lend
support to studies that indicate that IFN-γ and IL-4 responses to
MV are mediated primarily by CD4+ T cells with a Th1-like
phenotype and that depletion of CD4 cells prior to measles
stimulation completely abrogated IFN-γ and IL-4 production
(Howe et al., 2005a). Other studies have suggested that upon
secondary in vitromeasles stimulation, memory T cells generate
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IL-4 and resemble Th1/Th0-like cells (Howe et al., 2005b). We
also found that children who were homozygous at the DQA1
locus had marginally higher measles-specific IL-10 levels
compared with children who were heterozygous for DQA1. A
different pattern was observed for class I HLA homozygosity.
With one exception, there was no significant association
between class I HLA homozygosity and cytokine secretion
levels after two doses of measles vaccine. Children who were
homozygous at the class IA locus had marginally lower IL-4
secreted levels compared with children who were heterozygous
at this locus. Furthermore, neither single nor multilocus
homozygosity was associated with measles-induced low IL-2
and IL-12p40 secretion levels. The observed low IL-2 and
IL-12p40 secretion levels may indicate that MV infection
suppresses IL-2 and IL-12 in vitro production by peripheral
blood mononuclear cells (PBMC). Additionally, multilocus
homozygosity was not associated with measles-induced IL-4
and IL-10 secretion levels.
It has been speculated that the lack of any effect of HLA
class I homozygosity may reflect lesser contributions of
individual polymorphic class I alleles in cytokine immune
responses to measles (Tang et al., 1999). In any event, the
variable binding affinities to polymorphic HLA molecules and
polymorphisms in effector molecules, such as cytokines and
other co-stimulatory molecules, may play a role in the immune
response to vaccines (Wang et al., 2004; Schuenke et al.,
1998; Lindemann et al., 2002). We examined associations of
eight HLA loci with each of five different cytokine secretion
values, resulting in a total of 40 locus-specific tests of
homozygosity; thus, multiple testing issues exist. We found
four statistically significant associations, about twice as many
as we would expect by chance, and all four involved IFN-γ
cytokine secretion. In each, homozygosity was further
associated with increased IFN-γ secretion levels.
The outcome of this study to some extent is in agreement
with our earlier study demonstrating that a two-dose vaccination
regimen may overcome the barrier of HLA homozygosity on
single dose measles vaccine-induced low antibody levels (St.
Sauver et al., 2005). This extinction of the so-called HLA
homozygote disadvantage is an interesting finding. The lack of
HLA diversity might reduce the repertoire of naturally
processed viral epitopes that can be presented to T helper or
T cytotoxic lymphocytes, resulting in a decreased immune
response to viral antigens (Carrington and O'Brien, 2003).
However, we found no statistical support for a heterozygous
advantage based on HLA class I and class II loci and cytokine
immune responses to measles vaccine. Our results suggest that a
two-dose vaccination schedule seems to induce measurable
measles-specific cytokine immune responses, despite HLA
homozygosity status. As we have observed in a previous study,
measles antibody levels following two doses of MMR vaccine
were correlated with lymphoproliferation (r=0.12, p=0.03),
but lacked any correlation with the measures of IFN-γ and IL-4
secretion. Alternatively, a significant correlation was found
between lymphoproliferation and IFN-γ (r=0.20, p=0.0002)
and IL-4 (r=0.15, p=0.005) secretion (Dhiman et al., 2005).Various combinations of polymorphic HLA molecules are
involved in shaping the course of immune responses to
measles, mainly by controlling humoral and cellular immune
responses to the virus (Tang et al., 1999). In this context,
Kaslow et al. (2001) demonstrated that class I HLA
homozygosity was not significantly disadvantageous when
analyzed for response to ALVAC-HIV recombinant canarypox
vaccine. In the case of hepatitis B virus (HBV) vaccination,
there was overrepresentation of homozygotes for HLA-A1,
HLA-B8, HLA-DR3 and HLA-DQ2 alleles in non-responders
to this vaccine (Vingerhoets et al., 1995; Stachowski et al.,
1995). Early papers found evidence that PBMC from HBV
non-responders did not produce Th1 (IL-2 and IFN-γ)
cytokines after hepatitis B surface antigen (HBsAg) stimula-
tion (Vingerhoets et al., 1994). To our knowledge, the
relationship between HLA homozygosity and secreted
cytokines has not been previously studied for measles. We
cannot, however, evaluate the relative contributions of
individual HLA molecules to cytokine production following
measles immunization. We speculate that homozygotes for
specific HLA alleles of the DRB1, DQA1, DPA1 or DPB1
loci could present a similar or broader range of MV-derived
peptides compared to certain heterozygotes (Tang et al.,
1999). In fact, peptides that differ in sequence but share
multiple key amino acid motifs capable of fitting into key
HLA anchoring pockets may be bound by the same HLA
molecule (“peptide promiscuity”) (Hill et al., 1994; O'Sulli-
van et al., 1991; Sidney et al., 1995; Marshall et al., 1994).
Studies have demonstrated that different peptides can be
bound by the same HLA molecule (Hughes et al., 1996;
Yassine-Diab et al., 1999) and each HLA allele “binds an
overlapping but distinct set of peptides, with a resultant
unique potential immune repertoire,” (Nepom et al., 1996)
and has “a readily distinguishable and reproducible peptide
profile” (Chicz et al., 1993). Similarly, recognition of viral
peptides with “dual” specificity (for example, binding to both
class IA and DRB1 alleles), which elicit both HLA class I-
and class II-restricted immune responses, can add to the
complexity of our findings (Sette et al., 1991). On the other
hand, no significant heritability was observed for the IFN-γ
responses to the naturally derived immunodominant epitope
from the Mycobacterium tuberculosis Ag85B that can be
presented in a promiscuous manner by multiple HLA class II
molecules encoded by the DRB1, DRB3, and DRB4 genes
(Mustafa et al., 2000). Nonetheless, the existence of HLA
class I and II supertypes (Sette and Sidney, 1999; Sidney et
al., 1996; Ou et al., 1998) and the description of HLA alleles
capable of sharing overlapping peptide-binding specificities
(Sidney et al., 1995; Southwood et al., 1998), could facilitate
our understanding of the genetic effect of HLA homozygosity
on vaccine immune response.
Limitations of our study include lack of data on the in vitro
cytokine response profile and correlation with antibody titers in
the vaccine recipients. In addition, measles-specific cytokine
production can be transient and any differences can be obscured
by using cell culture supernatants from frozen PBMC. None-
theless, results from our population-based study suggest that
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vaccine-induced cytokine responses and instead was associated
with increased IFN-γ levels. Further studies are required to
answer the question whether HLA homozygosity may affect
vaccine-generated CD8 and CD4 cytotoxic T lymphocyte
response against MV. It is important that our results be validated
in a larger study population, since confirmation that HLA
homozygosity is not disadvantageous may simplify novel
vaccine development.
In conclusion, our results suggest that homozygosity at class
I and class II loci showed no disadvantage for measles vaccine-
induced cytokine immune responses following two doses of the
MMR vaccine. Therefore, live measles vaccine is an effective
vaccine inducing measurable cytokine immune responses after
two doses of the vaccine, in spite of HLA homozygosity status.
Further studies should clarify whether these observations are
generalizable to other viral vaccines, such as mumps and rubella.
A better characterization of such host genetic profile markers
that influence the outcome of vaccine immune responses will
support further vaccine development and application.
Materials and methods
Study subjects
Details of our subject recruitment have been published
elsewhere (Ovsyannikova et al., 2004a; St.Sauver et al., 2005,
in press). In brief, we enrolled 346 healthy children (age 12 to
18 years) identified through the Minnesota Independent School
District 535 registration rolls. HLA and cytokine secretion data
were available on 339 subjects. Measles vaccination was part
of a routine program and all enrolled participants had
documentation in their medical records of having received
two doses of live measles–mumps–rubella (MMR) vaccine
(Merck Research, West Point, PA) containing the attenuated
Edmonston B strain of MV (≥1000 TCID50). Mayo Clinic's
Institutional Review Board granted approval for the study, and
blood samples were drawn after informed consent, permission,
and assent were obtained as appropriate from the subjects and
their parents.
In vitro IFN-γ, IL-2, IL-4, IL-10 and IL-12p40 cytokine
responses to measles
Cytokine responses to MV were measured as described
previously (Ovsyannikova et al., 2005). Briefly, PBMC were
separated from heparinized venous blood by Ficoll-Hypaque
(Sigma, St. Louis, MO) density gradient centrifugation. Cells
were resuspended in RPMI 1640 (Celox Laboratories Inc., St.
Paul, MN) freezing media containing 10% dimethyl sulfoxide
(Sigma, St. Louis, MO) and 20% heat-inactivated fetal calf
serum (FCS), frozen at −80 °C, and stored in liquid nitrogen.
For IFN-γ and IL-12p40 cytokine determination, PBMC
were cultured at a concentration of 2×105 cells/well in triplicate
with either media or Edmonston B vaccine strain of MV (virus
stock of 1×107 plaque-forming units [pfu]/ml) diluted in RPMI
1640 supplemented with 1% normal human serum (NHS) at amultiplicity of infection (MOI) of 0.5. In optimization experi-
ments no differences were observed in secreted cytokine
responses in the control cell cultures in the presence of RPMI
1640 media versus equivalent Vero cell lysate. Cytokine
IL-12p40 was selected since the decrease in IL-12 production by
monocytes was shown to be greater when the p40 monomer was
measured rather than the bioreactive p70 heterodimer (Karp et
al., 1996; Polack et al., 2002). For IL-4 determination, cells were
cultured at a concentration of 4×105 cells/well in duplicate in
the presence of 2 μg/ml of monoclonal IL-4 receptor antibody
(mAb) (R&D Systems, Minneapolis, MN) with or without MV
diluted in RPMI 1640 supplemented with 1% NHS at a MOI of
0.1 as previously described (Dhiman et al., 2004). For
determination of secreted IL-2 and IL-10, PBMC (4×105
cells/well) were cultured in duplicate with or without MV (MOI
of 0.1). Stimulation with 5 μg/ml phytohemagglutinin (PHA)
was used as a positive control in selected subjects. Cell-free
supernatants were collected on day 6 and MV-specific IFN-γ,
IL-2, IL-4, IL-10, and IL-12p40 responses were quantitatively
determined by ELISA following the manufacturer's protocol
(BD Pharmingen, San Diego, CA). The levels of sensitivity for
the IFN-γ, IL-2, IL-4, IL-10, and IL-12p40 assays were 4.7 pg/
ml, 4 pg/ml, 7.8 pg/ml, 4 pg/ml, and 4 pg/ml, respectively.
Median background levels of IFN-γ, IL-2, IL-4, IL-10, and
IL-12p40 cytokine production in cultures not stimulated with
MV were subtracted from the median measles-induced
responses to produce corrected secretion values. Negative
corrected values indicate that the unstimulated secretion levels
were, on average, higher than the stimulated secretion levels.
DNA extraction and HLA typing
Details of HLA typing have been published elsewhere
(Ovsyannikova et al., 2004a). High-molecular-weight genomic
DNA was extracted from blood samples using a commercial
Puregene DNA extraction kit (Gentra Systems Inc., Minnea-
polis, MN). High-resolution polymerase chain reaction with
sequence-specific primer (PCR–SSP) was performed for HLA
class I and class II typing using SSP UniTray typing kits (Dynal
Biotech, Brown Deer, WI). Ambiguous allele combinations
were resolved by utilizing DNA sequencing kits and/or by
utilizing a group-specific primary (AmbiSolv) amplification
approach. All PCR performed with negative controls and every
50th PCR reaction was repeated for quality control. Homo-
zygosity was declared for individuals when they carried two
copies of the same allele, using the four-digit molecular
designation of HLA alleles.
Statistical analysis
Five outcomes, in two major classes of cytokine responses to
MV, were of primary interest: Th1 (IFN-γ, IL-2, and IL-12p40)
and Th2 (IL-4 and IL-10). Levels of each of these cytokines
were measured in supernatants in units of picograms per
milliliter. Data were descriptively summarized using fre-
quencies and percentages for all categorical variables and
medians and inter-quartile ranges for all continuous variables.
93I.G. Ovsyannikova et al. / Virology 364 (2007) 87–94Associations of cytokine response with gender were assessed
using analysis of variance methods. Due to data skewness, all
p-values were calculated using rank-transformed values.
Associations of homozygosity with gender were assessed
using Chi-square tests of significance.
We compared levels of cytokine secretion in homozygous
versus heterozygous individuals using linear regression techniques.
Variables representing locus-specific homozygosity status were
created for each of the eight availableHLA loci.We first fit separate
models for each of the loci individually. We then created a variable
indicatingwhether a subject was homozygous for at least one of the
loci and assessed its relationship with cytokine secretion. The
DPA1 locus was not considered in this latter assessment due to its
high degree of homozygosity. We then calculated a homozygosity
count for each subject. Values of this count could range from 0 to 8,
depending on the number of loci for which the subject was
homozygous. However, because of sparseness of data, individuals
homozygous for five or more loci were grouped with those
homozygous for four loci. We used this count variable to assess the
possible dose–response relationship between homozygosity and
cytokine secretion by fitting the count as a one degree-of-freedom
ordinal variable. Again because of data skewness, all p-values were
calculated using rank-transformed values. All analyses accounted
for the effects of the following set of potential confounding
variables by including each as a covariate in the linear regression
models: age at study enrollment, gender, age at first MMR
vaccination, age at secondMMR vaccination, and race. Finally, the
statistical tests described above assume that the two alleles from
each subject are independent; that is, genotype proportions fit
Hardy–Weinberg proportions. We tested this assumption using the
software HWE (Guo and Thompson, 1992). All statistical tests
were two-sided, and all analyses were carried out using the SAS
software system (SAS Institute, Inc., Cary, NC).
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